Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Madrigal Pharmaceuticals, Inc. (MDGL) Healthcare & Pipeline Overview

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in therapies for liver, metabolic, and cardiovascular diseases, with a primary focus on resmetirom for NASH. The company's selective thyroid hormone receptor-ß agonist approach positions it uniquely within the competitive biotechnology landscape.

What Is the Investment Thesis for MDGL?

Madrigal Pharmaceuticals presents a notable research candidate centered on the potential approval and commercialization of resmetirom for NASH. The successful completion of Phase III clinical trials and subsequent regulatory approval could drive significant revenue growth. With a market capitalization of $12.3B, Madrigal's valuation is heavily dependent on the success of resmetirom. Key value drivers include positive clinical trial data, regulatory approval timelines, and market penetration in the NASH treatment landscape. The company's high gross margin of 93.1% suggests strong profitability potential upon commercialization. However, the negative beta of -1.01 indicates an inverse correlation with the market, which could be a risk during market upturns. Investors should closely monitor clinical trial results and regulatory milestones to assess the risk-reward profile.

Based on FMP financials and quantitative analysis

MDGL Key Highlights

Market Cap of $12.3B reflects investor expectations for resmetirom's potential in the NASH market.

• Gross Margin of 93.1% indicates a strong potential for profitability upon commercialization of resmetirom.
• Profit Margin of -27.3% highlights the company's current investment in research and development.
• Lead product candidate, resmetirom, is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis (NASH).
• The company has a research, development, and commercialization agreement with Hoffmann-La Roche.

Who Are MDGL's Competitors?

MDGL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MDGL's Key Strengths?

Lead product candidate, resmetirom, in Phase III clinical trials.

• Strong gross margin potential upon commercialization.
• Partnership with Hoffmann-La Roche.
• Proprietary drug development platform.

What Are MDGL's Weaknesses?

Currently operating at a loss with a negative profit margin.

• Reliance on the success of a single lead product candidate.
• High R&D expenses.
• Negative beta indicates inverse market correlation.

What Could Drive MDGL Stock Higher?

Completion of Phase III clinical trials for resmetirom.

• Regulatory submission and potential approval of resmetirom.
• Expansion of research and development efforts.
• Strategic partnerships and collaborations.

What Are the Key Risks for MDGL?

Negative return on equity (-50.2%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Rich valuation — a P/E of 40.15 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.
• Clinical trial failures or delays.
• Regulatory hurdles and approval delays.
• Competition from other companies developing NASH treatments.
• Adverse events or safety concerns related to resmetirom.
• Dependence on the success of a single lead product candidate.

What Are the Growth Opportunities for MDGL?

• Successful Commercialization of Resmetirom: The primary growth driver for Madrigal is the successful commercialization of resmetirom upon regulatory approval. The timeline for this growth is dependent on the completion of Phase III trials and subsequent regulatory review, expected within the next 1-2 years. Madrigal's competitive advantage lies in the potential efficacy and safety profile of resmetirom.
• Expansion into New Therapeutic Areas: Madrigal has the opportunity to leverage its expertise in liver and metabolic diseases to expand into new therapeutic areas. This could involve developing new drug candidates or acquiring existing assets. The market size for related metabolic diseases is significant, providing a long-term growth avenue for the company. This expansion could begin within the next 3-5 years, depending on the success of resmetirom and the company's strategic priorities.
• Partnerships and Collaborations: Madrigal can pursue strategic partnerships and collaborations to accelerate its research and development efforts. The existing agreement with Hoffmann-La Roche demonstrates the company's ability to attract partnerships with major pharmaceutical companies. These collaborations can provide access to funding, expertise, and commercialization resources. The timeline for new partnerships is ongoing, as Madrigal continues to explore opportunities to enhance its pipeline.
• Geographic Expansion: Madrigal has the potential to expand its geographic reach beyond the United States. The prevalence of NASH is increasing globally, creating opportunities to commercialize resmetirom in international markets. This expansion could involve establishing a direct sales force or partnering with local distributors. The timeline for geographic expansion is dependent on regulatory approvals in different countries, which could occur within the next 2-3 years.
• Development of MGL-3745: Madrigal's backup compound to resmetirom, MGL-3745, represents a potential growth opportunity. If resmetirom faces any setbacks or limitations, MGL-3745 could serve as an alternative treatment option. The development of MGL-3745 is currently in earlier stages, with a longer-term timeline for potential commercialization. This provides Madrigal with a degree of risk mitigation and a potential second product in the liver disease space.

What Are MDGL's Competitive Advantages?

• Proprietary drug development platform.
• Strong intellectual property protection for resmetirom.
• Advanced clinical development stage for lead product candidate.
• Established partnership with Hoffmann-La Roche.

What Does MDGL Do?

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of serious cardiometabolic and liver diseases. The company's primary focus is on non-alcoholic steatohepatitis (NASH), a liver disease with a high unmet medical need. Madrigal's lead product candidate, resmetirom, is a liver-directed, selective thyroid hormone receptor-ß agonist designed to improve liver function and reduce fibrosis in NASH patients. Resmetirom is currently in Phase III clinical trials, evaluating its safety and efficacy in a broad range of NASH patients. The company also develops MGL-3745, a backup compound to resmetirom. Madrigal was founded with the vision of addressing significant gaps in the treatment of liver and metabolic disorders. Through strategic research and development, the company has advanced resmetirom to late-stage clinical development, positioning itself as a potential leader in the NASH treatment landscape. Madrigal has a research, development, and commercialization agreement with Hoffmann-La Roche. Headquartered in West Conshohocken, Pennsylvania, Madrigal Pharmaceuticals continues to expand its research efforts and clinical programs to address the growing global burden of liver and metabolic diseases.

What Products and Services Does MDGL Offer?

• Develop therapeutic candidates for cardiovascular diseases.
• Develop therapeutic candidates for metabolic diseases.
• Develop therapeutic candidates for liver diseases.
• Focus on non-alcoholic steatohepatitis (NASH) treatment.
• Develop liver-directed selective thyroid hormone receptor-ß agonists.
• Conduct Phase III clinical trials for resmetirom.

How Does MDGL Make Money?

• Develop and commercialize pharmaceutical products.
• Generate revenue through sales of approved therapies.
• Partner with other pharmaceutical companies for research and commercialization.
• Focus on licensing and collaboration agreements.

What Industry Does MDGL Operate In?

Madrigal Pharmaceuticals operates within the biotechnology industry, specifically targeting the liver disease market. The NASH market is characterized by a high unmet medical need and a growing prevalence of the disease. The competitive landscape includes companies like Moderna, Inc. (MRNA) and Abivax S.A. (ABVX), which are also developing NASH treatments. The industry is driven by advancements in drug development and increasing awareness of liver diseases. Madrigal's selective thyroid hormone receptor-ß agonist approach positions it uniquely within this competitive environment.

Who Are MDGL's Key Customers?

• Patients with cardiovascular diseases.
• Patients with metabolic diseases.
• Patients with liver diseases, particularly NASH.
• Healthcare providers prescribing treatments for these conditions.

Over the past six months, Madrigal Pharmaceuticals, Inc. insiders filed 42 SEC Form 4 transactions — 26 sales and 16 purchases. On net that is roughly 306 shares acquired (about $2.4M) — insiders putting money in tends to read as conviction.

Madrigal Pharmaceuticals, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 814.8% below estimates on average.

Madrigal Pharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 9.02 places it in the safe zone, indicating low near-term bankruptcy risk.

Return on equity for Madrigal Pharmaceuticals, Inc. stands at -50.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -25.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -2.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.50 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.0%, the inverse of the P/E and a quick read on earnings relative to price.

Madrigal Pharmaceuticals, Inc. (MDGL) Valuation Context

Valued at $12.3B, MDGL is classified as a large-cap stock. Analyst price targets span from $542.00 to $962.00, with a consensus of $677.00. At the current price of $533.12, that implies approximately 27% upside potential. Relative to its peer group, MDGL's quantitative score of 33/100 is below the peer average of 71/100.

MDGL Revenue & Earnings Trend

In Q2 FY2026, MDGL generated $364.3M in top-line revenue, marking a sequential increase of 17.0%. The company recorded a net loss of $57.9M, with diluted EPS of $-1.99. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, MDGL averaged $-3.23 in diluted EPS.

Company Profile

Madrigal Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in West Conshohocken, US. The company is led by CEO William J. Sibold. MDGL has traded publicly since 2007.

MDGL Financials

MDGL Latest News

MDGL Analyst Consensus

MDGL MoonshotScore

Common Questions About MDGL (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources